| Identification | Back Directory | [Name]
SB 222200 | [CAS]
174635-69-9 | [Synonyms]
CS-1124
SB 222200
SB-222200; SB222200
(S)-3-METHYL-2-PHENYL-N-(1-PHENYLPROPYL)-4-QUINOLINECARBOXAMIDE
3-METHYL-2-PHENYL-N-[(1S)-1-PHENYLPROPYL]-4-QUINOLINECARBOXAMIDE
3-Methyl-2-phenyl-N-((1S)-1-phenylpropyl)quinoline-4-carboxamide
4-Quinolinecarboxamide, 3-methyl-2-phenyl-N-[(1S)-1-phenylpropyl]-
SB222200//3-Methyl-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxaMide | [Molecular Formula]
C26H24N2O | [MDL Number]
MFCD00944072 | [MOL File]
174635-69-9.mol | [Molecular Weight]
380.48 |
| Chemical Properties | Back Directory | [Melting point ]
154℃ | [Boiling point ]
553.5±50.0 °C(Predicted) | [density ]
1.142 | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
DMSO: ~28 mg/mL, soluble
| [form ]
solid
| [pka]
12.88±0.46(Predicted) | [color ]
light yellow
|
| Hazard Information | Back Directory | [Uses]
3-Methyl-2-phenyl-N-[(1S)-1-phenylpropyl]-4-quinolinecarboxamide is a chemical agent used in the preparation of acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor as antipsychotics (1,2). | [Definition]
ChEBI: 3-methyl-2-phenyl-N-[(1S)-1-phenylpropyl]-4-quinolinecarboxamide is a member of quinolines. | [Biological Activity]
Potent and selective non-peptide NK 3 receptor antagonist. K i values are 4.4, >100,000 and 250 nM for human NK 3 , NK 1 and NK 2 receptors respectively. Brain penetrant and active in vivo . | [in vivo]
SB-222200 (5 mg/kg; 30 min pretreatment) produces inhibition of behavioral responses induced by NK-3 receptor-selective agonist senktide (HY-P0187) in mice[1].
SB-2222006 exhibits moderate oral bioavailability (rat 46%) and Cmax (rat 427 ng/mL) following oral administration (rat 10 mg/kg)[1].
SB-2222006 exhibits terminal elimination half-life (rat 1.9 h) due to high plasma clearance (56 mL/min/kg) following intravenous administration (rat 2.5 mg/kg)[1].
| Animal Model: | Male BALB/c mice (19-21 g)[1] | | Dosage: | 5 mg/kg | | Administration: | Oral administration | | Result: | Produced 57% inhibition of senktide-induced behavioral responses in mice. |
| Animal Model: | Male Sprague-Dawley rats (300-400 g)[1] | | Dosage: | 2.5 mg/kg for i.v.; 10 mg/kg for p.o. (Pharmacokinetic Analysis) | | Administration: | Intravenous injection and oral gavage | | Result: | Oral bioavailability (46%), T1/2 (1.9 h), Cmax (427 ng/mL). |
| [IC 50]
NK3 | [storage]
Store at RT |
|
| Company Name: |
|
| Tel: |
821-50328103-801 18930552037 |
| Website: |
http://www.yuhua99.com/ShowSupplierProductsList13285/0.htm |
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|